Constantinides Vasilios C, Boufidou Fotini, Bourbouli Mara, Pyrgelis Efstratios-Stylianos, Ghika Apostolia, Koros Christos, Liakakis George, Papageorgiou Sokratis, Stefanis Leonidas, Paraskevas George P, Kapaki Elisabeth
First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Vass. Sophias Ave. 74, 11528 Athens, Greece.
Neurochemistry and Biological Markers Unit, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Vass. Sophias Ave. 74, 11528 Athens, Greece.
Diagnostics (Basel). 2023 Jan 17;13(3):332. doi: 10.3390/diagnostics13030332.
Patients with a frontotemporal lobar degeneration (FTLD) usually manifest with behavioral variant frontotemporal dementia (bvFTD). Alzheimer's disease (AD) may also manifest with a predominant behavioral-dysexecutive syndrome, similar to bvFTD. Cerebrospinal fluid (CSF) biomarkers, such as total tau (τ), phosphorylated tau (τ) and amyloid beta with 42 amino-acids (Aβ), can predict AD pathology in vivo. The aim of this study was to compare the τ/Aβ and τ/Aβ ratios, the BIOMARKAPD/ABSI criteria and the AT(N) classification system in a cohort of bvFTD patients.
A total of 105 bvFTD patients (21 possible bvFTD; 20%) with CSF data, examined from 2008 to 2022, were included. Seventy-eight AD patients and 62 control subjects were included. The CSF biomarkers were measured with Innotest (2008-2017 subcohort) and EUROIMMUN (2017-2022 subcohort) ELISAs.
Depending on the classification system, 7.6 to 28.6% of bvFTD had an AD biochemical profile. The τ/Aβ and τ/Aβ ratios classified more patients as AD compared to the BIOMARKAPD/ABSI and AT(N) systems. The patients with possible bvFTD had higher frequencies of AD compared to the probable bvFTD patients.
The four classification criteria of CSF AD biomarkers resulted in differences in AD allocation in this bvFTD cohort. A consensus on the optimal classification criteria of CSF AD biomarkers is pivotal.
额颞叶变性（FTLD）患者通常表现为行为变异型额颞叶痴呆（bvFTD）。阿尔茨海默病（AD）也可能表现为以行为-执行功能障碍为主的综合征，类似于bvFTD。脑脊液（CSF）生物标志物，如总tau蛋白（τ）、磷酸化tau蛋白（τ）和42个氨基酸的淀粉样β蛋白（Aβ），可以在体内预测AD病理。本研究的目的是比较一组bvFTD患者的τ/Aβ和τ/Aβ比值、BIOMARKAPD/ABSI标准和AT（N）分类系统。
纳入了2008年至2022年期间检查的105例有CSF数据的bvFTD患者（21例可能为bvFTD，占20%）。纳入了78例AD患者和62例对照受试者。使用Innotest（2008 - 2017年亚组）和EUROIMMUN（2017 - 2022年亚组）酶联免疫吸附测定法测量CSF生物标志物。
根据分类系统，7.6%至28.6%的bvFTD患者具有AD生化特征。与BIOMARKAPD/ABSI和AT（N）系统相比，τ/Aβ和τ/Aβ比值将更多患者分类为AD。与可能的bvFTD患者相比，可能为bvFTD的患者AD发生率更高。
CSF AD生物标志物的四种分类标准导致该bvFTD队列中AD分配存在差异。就CSF AD生物标志物的最佳分类标准达成共识至关重要。
